Search

01/04/2024 CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine
García-Azorín, D, Martínez-Badillo, C, Muñiz, JC, Gago-Veiga, AB, Sánchez, NM, González-Quintanilla, V, Porta-Etessam, J, Sierra-Mencia, A, Gonzalez-Garcia, N, González-Osorio, Y, Polanco-Fernandez, M, Recio-García, A, Nieto, RB, Guerrero-Peral, AL. CandeSpartan Study: Candesartan Spanish Response-prediction and Tolerability study in migraine. CEPHALALGIA. 2024; 44(4)DOI:10.1177/03331024241248833. PMID:38663908. IF:4.600(Q1/2D).
28/03/2024 A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors
Swift, IJ, Rademakers, R, Finch, N, Baker, M, Ghidoni, R, Benussi, L, Binetti, G, Rossi, G, Synofzik, M, Wilke, C, Mengel, D, Graff, C, Takada, LT, Sanchez-Valle, R, Antonell, A, Galimberti, D, Fenoglio, C, Serpente, M, Arcaro, M, Schreiber, S, Vielhaber, S, Arndt, P, Santana, I, Almeida, MR, Moreno, F, Barandiaran, M, Gabilondo, A, Stubert, J, Gomez-Tortosa, E, Agueero, P, Sainz, MJ, Gohda, T, Murakoshi, M, Kamei, N, Kittel-Schneider, S, Reif, A, Weigl, J, Jian, JL, Liu, CJ, Serrero, G, Greither, T, Theil, G, Lohmann, E, Gazzina, S, Bagnoli, S, Coppola, G, Bruni, A, Quante, M, Kiess, W, Hiemisch, A, Jurkutat, A, Block, MS, Carlson, AM, Bråthen, G, Sando, SB, Grontvedt, GR, Lauridsen, C, Heslegrave, A, Heller, C, Abel, E, Gómez-Núñez, A, Puey, R, Arighi, A, Rotondo, E, Jiskoot, LC, Meeter, LHH, Duraes, J, Lima, M, Tábuas-Pereira, M, Lemos, J, Boeve, B, Petersen, RC, Dickson, DW, Graff-Radford, NR, Leber, I, Sellami, L, Lamari, F, Clot, F, Borroni, B, Cantoni, V, Rivolta, J, Lleó, A, Fortea, J, Alcolea, D, Illán-Gala, I, Andres-Cerezo, L, Van Damme, P, Clarimon, J, Steinacker, P, Feneberg, E, Otto, M, van der Ende, EL, van Swieten, JC, Seelaar, H, Zetterberg, H, Sogorb-Esteve, A, Rohrer, JD. A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors. Alzheimers Research & Therapy. 2024; 16(1)DOI:10.1186/s13195-024-01420-z. PMID:38539243. IF:7.600(Q1/1D).
08/03/2024 Cortical Macro- and Microstructural Changes in Parkinson's Disease with Probable Rapid Eye Movement Sleep Behavior Disorder
Pardo, J, Montal, V, Campabadal, A, Oltra, J, Uribe, C, Roura, I, Bargalló, N, Martí, MJ, Compta, Y, Iranzo, A, Fortea, J, Junqué, C, Segura, B. Cortical Macro- and Microstructural Changes in Parkinson's Disease with Probable Rapid Eye Movement Sleep Behavior Disorder. MOVEMENT DISORDERS. 2024; 39(5)DOI:10.1002/mds.29761. PMID:38456361. IF:7.600(Q1/1D).
01/03/2024 Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton N.J., Brum W.S., Di Molfetta G., Benedet A.L., Arslan B., Jonaitis E., Langhough R.E., Cody K., Wilson R., Carlsson C.M., Vanmechelen E., Montoliu-Gaya L., Lantero-Rodriguez J., Rahmouni N., Tissot C., Stevenson J., Servaes S., Therriault J., Pascoal T., Lleó A., Alcolea D., Fortea J., Rosa-Neto P., Johnson S., Jeromin A., Blennow K., Zetterberg H.. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurology. 2024; 81(3)DOI:10.1001/jamaneurol.2023.5319. PMID:38252443. IF:21.300(Q1/1D).
01/02/2024 Neural basis of speech and grammar symptoms in non-fluent variant primary progressive aphasia spectrum
Lorca-Puls DL, Gajardo-Vidal A, Mandelli ML, Illán-Gala I, Ezzes Z, Wauters LD, Battistella G, Bogley R, Ratnasiri B, Licata AE, Battista P, García AM, Tee BL, Lukic S, Boxer AL, Rosen HJ, Seeley WW, Grinberg LT, Spina S, Miller BL, Miller ZA, Henry ML, Dronkers NF, Gorno-Tempini ML. Neural basis of speech and grammar symptoms in non-fluent variant primary progressive aphasia spectrum. BRAIN. 2024; 147(2)DOI:10.1093/brain/awad327. PMID:37769652. IF:11.700(Q1/1D).
01/02/2024 Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease
Bejanin, A, Villain, N. Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease. LANCET NEUROLOGY. 2024; 23(2)DOI:10.1016/S1474-4422(23)00501-X. PMID:38267172. IF:45.500(Q1/1D).